FELIX GALLEGOS, CAMILO EDGAR VINICIO

Preferred name

Main Affiliation

Facultad de Ciencias de la Salud Eugenio Espejo

CENIEC - Grupo de Investigación de Enfermedades Crónicas

Web Site

Google Scholar

ORCID

0000-0003-0224-2321

Scopus Author ID

57210396829

Now showing 1 - 10 of 21

Some of the metrics are blocked by your
consent settings
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
(Elsevier BV, 2022-12)
John W Eikelboom
;
Sanjit S Jolly
;
Emilie P Belley-Cote
;
Richard P Whitlock
;
Sumathy Rangarajan
Some of the metrics are blocked by your
consent settings
Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial
(Elsevier BV, 2017-08)
Jackie Bosch
;
John W. Eikelboom
;
Stuart J. Connolly
;
Nancy Cook Bruns
;
Vivian Lanius
Some of the metrics are blocked by your
consent settings
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
(Oxford University Press (OUP), 2022-04-06)
John W Eikelboom
;
Jacqueline Bosch
;
Stuart J Connolly
;
Jessica Tyrwitt
;
Keith A A Fox
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Aims</jats:title> <jats:p>To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and results</jats:title> <jats:p>Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1–1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11–2.61], mortality 1.87 (1.65–2.10), stroke 0.62 (0.50–0.76), and MI 1.02 (0.86–1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86–1.19) and 2.49 (2.24–2.75), compared with 1.67 (1.48–1.87) and 5.11 (95% CI 4.77–5.47), respectively, during the randomized treatment phase with the combination.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.</jats:p> </jats:sec>
Some of the metrics are blocked by your
consent settings
The burden of cardiovascular events according to cardiovascular risk profile in adults from high-income, middle-income, and low-income countries - PURE: a cohort study
(Elsevier BV, 2025-08)
Darryl P Leong
;
Rita Yusuf
;
Romaina Iqbal
;
Alvaro Avezum
;
Afzalhussein Yusufali
Background: Current strategies to prevent adverse cardiovascular outcomes focus primary prevention in high-risk groups and secondary prevention in people with known cardiovascular disease. We aimed to determine the proportion of events occurring in lower-risk groups globally. Methods: We included people aged 40 years to younger than 75 years who were enrolled in the Prospective Urban Rural Epidemiology (PURE) study, which is an ongoing, international, prospective, population-based cohort study that started recruiting adults from households selected to be broadly representative of the sociodemographic composition of their communities. We prospectively documented fatal or non-fatal myocardial infarction, stroke, heart failure, or any other fatal cardiovascular event stratified by history of cardiovascular disease and by the 10-year predicted disease risk scores based on WHO 2019 laboratory risk tables (<10% [low], 10% to <20% [intermediate], and ≥20% [high]) in people without previous cardiovascular disease from 26 high-income, middle-income, and low-income countries. Outcome event rates were standardised for the cohort's age and sex distribution. Findings: Between July 11, 2000, and May 6, 2019, 128 973 participants were included from 26 countries (mean age 53·6 years [SD 8·2]; 75 858 [58·8%] were female and 53 115 [41·2%] were male). We observed 11 483 outcome events affecting 8·9% of the cohort during a median follow-up of 12·3 years (IQR 9·8–14·6). Among participants, 89 508 (69·4%) had a low cardiovascular disease risk, 22 363 (17·3%) had an intermediate cardiovascular disease risk, and 5529 (4·3%) had a high cardiovascular disease risk, while 11 573 (9·0%) had known cardiovascular disease. The age-standardised and sex-standardised cardiovascular disease incidence rates per 1000 person-years was 4·1 (95% CI 4·0–4·2) in the low-risk group, 17·7 (15·2–20·2) in the intermediate-risk group, and 40·8 (25·1–56·4) in the high-risk group. Overall, 41% of outcome events occurred in cardiovascular disease-naive participants at low risk. The proportion of adverse cardiovascular outcomes occurring in this low-risk group was inversely related to country income level (32% in high-income, 38% in middle-income, and 54% in low-income countries) and was higher in women (51%) than in men (32%). Interpretation: To achieve a substantial population-level reduction in cardiovascular disease, a fundamental change is needed, so that preventive strategies for cardiovascular disease extend beyond those at high or even intermediate predicted risk to include those at considered to be at low risk. Funding: The funding bodies are listed in the appendix (p 29).
Some of the metrics are blocked by your
consent settings
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
(Elsevier BV, 2021-07)
John W. Eikelboom
;
Deepak L. Bhatt
;
Keith A.A. Fox
;
Jacqueline Bosch
;
Stuart J. Connolly
Some of the metrics are blocked by your
consent settings
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis
(Ovid Technologies (Wolters Kluwer Health), 2019-10-29)
John W. Eikelboom
;
Stuart J. Connolly
;
Jacqueline Bosch
;
Olga Shestakovska
;
Victor Aboyans
<jats:sec> <jats:title>Background:</jats:title> <jats:p>Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the first manifestation of underlying cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) and determined the hazard of new cancer diagnosis after bleeding at these sites.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Of 27 395 patients enrolled (mean age, 68 years; women, 21%), 2678 (9.8%) experienced any (major or minor) bleeding, 713 (2.6%) experienced major bleeding, and 1084 (4.0%) were diagnosed with cancer during a mean follow-up of 23 months. Among 2678 who experienced bleeding, 257 (9.9%) were subsequently diagnosed with cancer. Gastrointestinal bleeding was associated with a 20-fold higher hazard of new gastrointestinal cancer diagnosis (7.4% versus 0.5%; hazard ratio [HR], 20.6 [95% CI, 15.2–27.8]) and 1.7-fold higher hazard of new nongastrointestinal cancer diagnosis (3.8% versus 3.1%; HR, 1.70 [95% CI, 1.20–2.40]). Genitourinary bleeding was associated with a 32-fold higher hazard of new genitourinary cancer diagnosis (15.8% versus 0.8%; HR, 32.5 [95% CI, 24.7–42.9]), and urinary bleeding was associated with a 98-fold higher hazard of new urinary cancer diagnosis (14.2% versus 0.2%; HR, 98.5; 95% CI, 68.0–142.7). Nongastrointestinal, nongenitourinary bleeding was associated with a 3-fold higher hazard of nongastrointestinal, nongenitourinary cancers (4.4% versus 1.9%; HR, 3.02 [95% CI, 2.32–3.91]).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>In patients with atherosclerosis treated with antithrombotic drugs, any gastrointestinal or genitourinary bleeding was associated with higher rates of new cancer diagnosis. Any gastrointestinal or genitourinary bleeding should prompt investigation for cancers at these sites.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trial Registration:</jats:title> <jats:p> URL: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> . Unique identifier: NCT01776424. </jats:p> </jats:sec>
Some of the metrics are blocked by your
consent settings
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
(Elsevier BV, 2022-06)
John Eikelboom
;
Sumathy Rangarajan
;
Sanjit S. Jolly
;
Emilie P. Belley-Cote
;
Richard Whitlock
Some of the metrics are blocked by your
consent settings
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
(Massachusetts Medical Society, 2017-10-05)
John W. Eikelboom
;
Stuart J. Connolly
;
Jackie Bosch
;
Gilles R. Dagenais
;
Robert G. Hart
Some of the metrics are blocked by your
consent settings
Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial
(Elsevier BV, 2021-08)
David Collister
;
Lawrence Mbuagbaw
;
Gordon Guyatt
;
P.J. Devereaux
;
Karthik K. Tennankore
Some of the metrics are blocked by your
consent settings
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
(Elsevier BV, 2022-12)
John W Eikelboom
;
Sanjit S Jolly
;
Emilie P Belley-Cote
;
Richard P Whitlock
;
Sumathy Rangarajan

FELIX GALLEGOS, CAMILO EDGAR VINICIO

Filters

Settings

Sort By

Results per page